京新药业: 关于股份回购进展公告

Group 1 - The company approved a share repurchase plan on January 8, 2025, with a total amount not less than RMB 200 million and not exceeding RMB 400 million [1][2] - The estimated number of shares to be repurchased is approximately 13.51 million to 27.03 million, accounting for 1.57% to 3.14% of the total share capital [1] - The implementation period for the repurchase plan is 12 months from the date of board approval [1] Group 2 - The total repurchase amount was adjusted to not less than RMB 350 million and not exceeding RMB 700 million [2] - The maximum repurchase price was revised from RMB 14.80 per share to RMB 14.47 per share, effective from May 29, 2025 [3] - The estimated number of shares to be repurchased under the new price cap is approximately 24.19 million to 48.38 million, accounting for 2.81% to 5.62% of the total share capital [3] Group 3 - As of June 30, 2025, the company repurchased 47.27 million shares, representing 5.49% of the total share capital, with a total transaction amount of RMB 608.72 million [3][4] - The highest purchase price was RMB 14.41 per share, and the lowest was RMB 11.86 per share [3] Group 4 - The repurchase is funded by the company's own funds and complies with relevant laws and regulations [4] - The company will continue to implement the repurchase plan based on market conditions and fulfill information disclosure obligations [5]